# US 2019/0314306 A1 · Systems and methods for treating vitiligo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314306 A1
- Document ID: US20190314306A1
- Status: Published application
- Kind: A1
- Application number: 16/392,348
- Filed: 2019-04-23
- Published: 2019-10-17
- Earliest claimed: 2016-07-01
- Assignees: Transdermal Biotechnology, Inc.
- Applicants: Transdermal Biotechnology, Inc.
- Inventors: Nicholas V. Perricone
- Web page: https://patentgrep.com/patent/US20190314306A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 8/36: Carboxylic acids; Salts or anhydrides thereof
- A61K 8/365: Hydroxycarboxylic acids; Ketocarboxylic acids
- A61K 8/553: {Phospholipids, e.g. lecithin}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 17/00: Drugs for dermatological disorders
- A61Q 19/04: for chemically tanning the skin (topical sun or radiation screening or tanning preparations A61Q17/04)
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present invention comprises a composition comprising pyruvic acid and/or a pyruvate salt. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

## Claims

### Claim at position 1

1-118. (canceled)

### Claim 119

A method, comprising:
applying, to the skin of a subject having vitiligo, a composition comprising an active agent for treating the vitiligo, the active agent comprising pyruvic acid and/or a pyruvate salt,
wherein the pyruvic acid and/or a pyruvate salt is present at less than about 0.2% by weight.

### Claim 120 (depends on 119)

The method of claim 119, wherein the composition comprises pyruvic acid.

### Claim 121 (depends on 119)

The method of claim 119, wherein the composition comprises a pyruvate salt.

### Claim 122 (depends on 119)

The method of claim 119, wherein the composition is in the form of a gel, lotion, cream, ointment, soap, or stick.

### Claim 123 (depends on 119)

The method of claim 119, wherein the formulation is substantially transparent.

### Claim 124 (depends on 119)

The method of claim 119, wherein the composition comprises a first phase and a second phase.

### Claim 125 (depends on 124)

The method of claim 124, wherein the formulation comprises an emulsion of the first phase and a second phase.

### Claim 126 (depends on 124)

The method of claim 124, wherein the formulation comprises a liquid crystal structure of the first phase and a second phase.

### Claim 127 (depends on 126)

The method of claim 126, wherein at least a portion of the liquid crystal structure is multilamellar.

### Claim 128 (depends on 119)

The method of claim 119, wherein the composition further comprises lecithin.

### Claim 129 (depends on 128)

The method of claim 128, wherein the lecithin is present at at least about 0.25% by weight of the formulation.

### Claim 130 (depends on 128)

The method of claim 128, wherein the lecithin comprises phosphatidylcholine.

### Claim 131 (depends on 128)

The method of claim 128, wherein the lecithin comprises polyenylphosphatidylcholine.

### Claim 132 (depends on 131)

The method of claim 131, wherein the polyenylphosphatidylcholine is present at no more than 15% by weight of the formulation.

### Claim 133 (depends on 119)

The method of claim 119, wherein the formulation further comprises an emulsifier.

### Claim 134 (depends on 119)

The method of claim 119, wherein the formulation further comprises a fatty acid ester.

### Claim 135 (depends on 119)

The method of claim 119, wherein the formulation further comprises a transdermal penetration enhancer.

### Claim 136 (depends on 119)

The method of claim 119, wherein the composition has a viscosity of at least about 20,000 cP.

### Claim 137 (depends on 119)

The method of claim 119, wherein the subject is human.
